Deviating from "production ready by 2019" is a big cause, and touting Cancet as a flagship asset with world class grades and low cost developmental potential is misleading at best. If it was such low risk when they pitched it to us the risk in this space must be crazy high for them to justify exploring cobalt assets which is pretty darn risky, from developing what was a surface grade, proven asset that will produce low cost spoduemene that will be processed with an exclusive and one of a kind partnership with another lithium company that uses exclusive and amazing sileach technology. Guess all that went out the window because the cost didn't justify it, but wait, wasn't it low risk, low cost? oh....
MTC Price at posting:
2.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)